Great expectations
- PMID: 35543181
- DOI: 10.1111/ajt.17048
Great expectations
Keywords: belatacept; clinical trials; donor-specific antibodies; renal function; transplantation.
Comment on
-
A pilot randomized controlled trial of de novo belatacept-based immunosuppression following anti-thymocyte globulin induction in lung transplantation.Am J Transplant. 2022 Jul;22(7):1884-1892. doi: 10.1111/ajt.17028. Epub 2022 Mar 22. Am J Transplant. 2022. PMID: 35286760 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Huang HJ, Schechtman K, Askar M, et al. A pilot randomized controlled trial of de novo belatacept-based immunosuppression following anti-thymocyte globulin induction in lung transplantation. Am J Transplant. In press.
-
- Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. J Med. 2016;374:333-343.
-
- Klintmalm GB, Feng S, Lake JR, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 2014;14:1817-1827.
-
- Stock PG, Mannon RB, Armstrong B, et al. Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: Results of a prospective, randomized clinical trial. Am J Transplant. 2020;20:1668-1678.
-
- Launay M, Guitard J, Dorent R, et al. Belatacept-based immunosuppression: A calcineurin inhibitor-sparing regimen in heart transplant recipients. Am J Transplant. 2020;20:553-563.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
